From HealthDay News
U.S. Food and Drug Administration approval of Afinitor (everolimus)
has been expanded to include people with progressive neuroendocrine tumors of the pancreas (PNET) that have spread to other parts of the body or cannot be removed by surgery, the agency said Friday.
PNET is slow-growing and rare, affecting fewer than 1,000 new patients in the United States each year, the FDA said in a news release.
Afinitor was previously FDA-approved for advanced kidney cancer and certain brain tumors that cannot be treated surgically.